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Quantitative assessment of the long-term
effect of photodynamic therapy in patients
with pathologic myopia
Abstract Background: In patients
with classic subfoveal choroidal neo-
vascularization (CNV) secondary to
pathologic myopia (PM), photody-
namic therapy (PDT) has been shown
to stabilize the visual acuity. We have
analyzed the long-term visual prog-
nosis after PDT in patients with CNV
secondary to PM. Methods: In a
retrospective study we reviewed the
clinical charts of 102 patients. PDT
was performed following the proce-
dures described in the VIP and TAP
study protocols. Follow-up examina-
tions and PDT treatment were sched-
uled in 3-month intervals. Indications
for retreatment were an active leaking
CNV in combination with visual
disturbances or visual loss. To assess
treatment effects we analyzed the
number of letters read on the ETDRS
charts. The primary efficacy outcome
was the proportion of eyes that had
fewer than eight letters loss or gain at
24 months. Secondary efficacy out-
comes included the proportion of eyes
that had fewer than 15 letters loss or
gain and the proportion of eyes that
had fewer than 30 letters loss or gain
at month 24. Results: One hundred
and two patients were included into
the study. Mean follow-up was 32.5±
5.7 months. Patients received an
average of 2.2 treatments from study
entry through the last follow-up,
resulting in a total of 221 PDT
sessions throughout the study. At 24
months 46% lost at least eight letters.
A loss of at least 15 (30) letters was
observed in 25% (8%). Improvement
of at least eight letters was noted in
8%. Larger improvements of at least
15 letters occurred only in 4% of
study eyes. Conclusion: Our study
suggests that PDT can increase the
chance of stabilizing or improving
vision compared with the placebo arm
of VIP trial.
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Introduction
Pathologic myopia (PM) is the most frequent cause of
choroidal neovascularization (CNV) in patients under 50
years of age. Approximately 60% of CNVare secondary to
PM in this age group [4]. PM is characterized by pro-
gressive increases in the axial length of the eye and highly
negative spherical equivalents (typically −6.0 dpt. or more
negative). CNV develop in 5–10% of patients with axial
length greater than 26.5 mm [6]. Most of those patients
present with classic CNV [15, 17].
The underlying cause of CNV in PM involves degen-
eration of Bruch’s membrane followed by the in-growths
of new vessels. Continued stretching and degeneration of
the choroid leads to the development of breaks in Bruch’s
membrane known as lacquer cracks [6]. In eyes with CNV
secondary to PM, these have been identified in approxi-
mately 80% of cases [15, 16]. The presence of these cracks
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allow vessels from the choriocapillaris to proliferate into
the subretinal space.
Studies show that although laser photocoagulation may
stabilize visual acuity in eyes with extrafoveal CNV sec-
ondary to PM [1, 5], there is no evidence to suggest ben-
efits in patients with subfoveal CNV[1, 5]. The studies on
laser photocoagulation in extrafoveal lesions also show a
high rate of recurrence and a risk of spontaneous pro-
gressive enlargement of the atrophic photocoagulation scar
leading to worsening of visual acuity [7]. In addition, laser
photocoagulation has recently been linked to the devel-
opment of new or expanded lacquer cracks in the region
of the laser scar [8]. In patients with subfoveal CNV sec-
ondary to PM, photodynamic therapy (PDT) with vertepor-
fin has been shown to stabilize and even improve visual
acuity [15, 16], thus providing themeans to treat a condition
for which no other treatment has been proven effective.
However, the 2-year results of the VIP study did not show
statistically significant differences between treated and
nontreated groups from the primary efficacy outcome [17].
We have analyzed in a retrospective study the long-term
visual prognosis after PDT in patients with CNV secondary
to PM.
Materials and methods
We reviewed the clinical charts of 102 patients treated with
PDT for subfoveal CNV secondary to PM between 1999
and 2003 in the outpatient department of the University Eye
Hospital Leipzig. Inclusion criteria were PM (−6.0 dpt or
more negative), the presence of a classic subfoveal CNV,
and a minimal follow-up of 24 months. PDT treatment with
verteporfin was performed following the procedures de-
scribed in the VIP and TAP study protocols. Follow-up
examinations were scheduled in 3-month intervals. PDT
treatment was performed at baseline and thereafter in
3-month intervals, if indicated. Indications for retreatment
were an active leaking CNV in fluorescein angiographic
studies in combination with visual disturbances or visual
loss. At each visit all patients underwent a complete eye
examination including a detailed medical and ocular his-
tory. Examinations included ETDRS visual acuity, binocular
ophthalmoscopy, fluorescein angiography with a scanning
laser ophthalmoscope (HRA, Heidelberg Eye Explorer,
Heidelberg Engineering, Dossenheim, Germany), and color
fundus photography. To assess treatment effects we an-
alyzed the number of letters read on the ETDRS charts. The
primary efficacy outcome was the proportion of eyes that
had fewer than eight letters loss or gain (approximately less
than 1.5 lines of visual acuity change corresponding to less
than a 1.5-times increase or decrease of the visual angle) at
24 months. Additionally, we analyzed the changes in visual
outcome at the last follow-up. Secondary efficacy outcomes
included the proportion of eyes that had fewer than 15
letters loss or gain (moderate loss or gain in visual acuity
approximately less than three lines of visual acuity change)
and the proportion of eyes that had fewer than 30 letters loss
or gain (approximately less than six lines of visual acuity
change) at month 24. To assess treatment effects we ana-
lyzed the size of the classic component of the CNV in all
angiograms. The size of the classic component of the CNV
was evaluated from early angiographic images (30 s) using
the tracking tool of the Heidelberg Eye Explorer (Heidel-
berg Engineering, Dossenheim, Germany). All measure-
ments were performed by two independent readers from the
Leipzig Photographic Reading Center with no clinical data
available. The study complied with the provisions of the
Declaration of Helsinki and the recommendations of the
local ethics committee.
Results
One hundred and two patients (37 male, 65 female) aged
from 18 to 83 (57±14.8) years with classic subfoveal CNV
due to PM were included into the study (Table 1). Myopia
ranged from −6.5 dpt to −25 dpt (mean: −12.5 dpt). Follow-
up ranged form 24 to 53 months (32.5±5.7 months). All
patients completed the month 24 examination, and 34
(33%) patients had a 36 months follow-up. Patients re-
ceived an average of 2.2 treatments from study entry
through the last follow-up , resulting in a total of 221 PDT
sessions throughout the study. The average number of ap-
plications of verteporfin treatment continued to decrease
through the second year from 2.8 by the month-12 exam-
inations to 0.9 by the month-24 examinations. At baseline,
the main presenting symptom was a decrease in visual
acuity. It was associated with metamorphopsia in all pa-
tients. Inability to read or drive, loss of stereopsis, altered
color vision, and flashes of light were common associated
symptoms. Initial visual acuity ranged from 30 to 75 letters
(55±11 letters; approximate Snellen equivalent: 20/80). At
the 12-month follow-up examination, visual acuity ranged
from 24 to 80 letters (mean 50±14 letters; approximate
Snellen equivalent: 20/100). After 24 months of follow-up,
visual acuity ranged from 15 to 79 letters (mean 48±15
letters; approximate Snellen equivalent: 20/100). At 36
months and thereafter, the mean visual acuity score was
stable at 46±16 letters (approximate Snellen equivalent:
20/125).
Table 1 Patient demographics
Number of patients 102
Female 65
Treated eye right 52
Age (years) 57.0±14.8
Follow up (months) 32.5±5.7
Number of treatments 221
Number of treatments per eye 2.2±0.9
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At 24 months 47 study eyes (46%) lost at least eight
letters (approximately 1.5 Snellen lines) of visual acuity. A
loss of at least 15 (30) letters of visual acuity was observed
in 25 (eight) study eyes (25%; 8%). At last follow-up 46
study eyes (46%) presented with a loss of at least eight
letters of visual acuity. Improvement of visual acuity of at
least eight letters was observed in eight study eyes (8%).
Larger improvements of visual acuity of at least 15 letters
occurred only in four study eyes (4%). A detailed distri-
bution of visual acuity changes in the present study at 24
months is presented in Table 2. Additionally, we included
the results from the myopic patients of the VIP Study as
historic controls in Table 2 [18]. Figure 1 shows the per-
centage of study eyes with at least eight letters of visual
acuity throughout 24 months at indicated time.
A 36-months follow-up had 34 (33%) patients. At this
time point 18 (53%) study eyes had a decrease of visual
acuity of eight letters or more. An improvement in visual
acuity of at least eight letters was observed in five study
eyes (15%). Visual acuity changes at 36 months are pre-
sented in detail in Table 3.
The assessment of the classic component of the CNV
from early angiographic images showed a size of 0.13–
2.14 mm2 (mean: 0.76±0.60 mm2) at baseline. At the
12-month visit the size of the classic component of the
CNV ranged from 0.10 to 9.30 mm2 (mean: 2.0±2.6 mm2)
and at 24 months from 0.12 to 9.42 mm2 (mean: 2.0±2.8
mm2). There were 40 (39%) patients with progression of
classic CNV beyond the area of the lesion identified at
baseline at the 24-month follow-up. The proportion of
lesions with absence of the classic CNV either within or
beyond the area of the lesion identified at baseline increased
from month 12 with 38 (37%) patients and to month-24
examination 40 (39%) patients.
Discussion
In our study we assessed the proportion of patients with
subfoveal CNV secondary to PM who developed changes
in their visual acuity following PDT. As in the VIP study
[15, 18], we chose as efficacy outcome the proportion of
eyes that had fewer than eight letters loss or gain at 24
months. Since in the TAP study [13, 14] the primary out-
come was a loss of 15 or more letters of visual acuity loss,
we evaluated these changes in visual acuity as well.
The difference between the primary outcome for patients
with CNV secondary to PM and secondary to age-related
macular degeneration as defined in the VIP and TAP study
was chosen because it was expected that eyes with sub-
foveal CNV due to PM were likely to lose less vision than
eyes with subfoveal CNV due to ARMD [15–17].
In previous studies the occurrence of subretinal fibrosis
(SRF) after PDT was analyzed in myopic eyes. Ruiz-
Moreno and Montero showed that highly myopic eyes with
subfoveal CNV treated with PDT have stable visual acuity
even through they develop SRF [12]. No correlation be-
tween the number of PDT treatments and anatomical and
functional results were found in this study [12]. Lanzetta
et al. (2004) found several factors for anatomical and func-
tional results such as changes of the retinal pigment epi-
thelium and choroidal vasculature involved in the treatment
and enhanced expression of vascular endothelial growth
factor [10]. In an other study Montero and Ruiz-Moreno
observed an influence of the age at onset but not of the
number of PDT treatments on the visual prognosis. This
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Fig. 1 Percentage with greater than or equal to eight-letter loss at
indicated time (data from VIP study [15, 18]).
Table 2 Percentage of changes in visual acuity at the month-24
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Table 3 Percentage of changes in visual acuity at the month-36
follow-up examination
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was explained with increased chorioretinal atrophy, espe-
cially in older patients [11].
In our study the average number of applications of ver-
teporfin treatment continued to decrease through the second
year from 2.8 by the month-12 examinations to 0.9 by the
month-24 examinations. This low treatment rate compared
with the VIP study [15–17] is similar with the current clin-
ical practice in most settings [2, 3, 9, 11, 12]. Barnes and
coworkers proposed that verteporfin therapy can be at least
as effective as reported in the literature and requires fewer
treatments than reported [2]. Cohen et al. reported a good
effect of a single PDT treatment with verteporfin, resulting
in involution of the CNVand improvement of visual acuity
in a follow-up period of about 17 months [3]. In a pro-
spective study in a Chinese population, visual results were
comparable with the VIP study. The average accumulative
PDT treatments required in 1 and 2 years were 1.7 and 2.3,
respectively [9]. This very low treatment rate compared
with the VIP study [17] and our current study could been
explained by ethnic differences.
Unlike the VIP investigation, our treatment allocation
was not random in nature, and there was no control group.
The visual outcome in our study was less favorable com-
pared with the results of the PDT-treated patients in the
VIP study. Only during the first 6 months of follow-up
was the outcome of our study group similar to the PDT-
treated patients in the VIP study. Thereafter, we noted a
continuous increase in the number of patients with visual
loss in our study. In the VIP study a stabilization of visual
acuity loss was noted after the 6-month follow-up. Com-
paring the number of patients with visual gain of five or
more letters, we found similar results. In our study only
16% of patients had a visual gain compared with 39% of
patients in the PDT-treated patients in the VIP study at the
24-month follow-up. Nevertheless, the number of patients
showing an increase in visual acuity is higher than in the
placebo arm of the VIP study. Reasons for the less favorable
outcome in our study include the relatively low retreatment
rate (2.2±0.9 total treatments per eye), the number of pa-
tients with excessive myopia (>15 dpt) in our population,
and the lower visual acuity at baseline. Especially, the total
number of treatments was very low in our population. This
may be due in part to the current reimbursement situation
for PDT treatment. Since PDT treatment for subfoveal CNV
secondary to PM is not covered by public health insurances,
most patients were unable to pay for more than one or two
PDT treatments. This explains the low number of total
treatments in our study.
Looking at the fluorescein angiograms during follow-up,
we found a similar rate of patients with progression of
classic CNV beyond the area of the lesion identified at
baseline (39% verteporfin-treated group Leipzig vs. 35%
verteporfin-treated group VIP study), but the verteporfin-
treated groups had a smaller proportion than the placebo
treated group in the VIP study (43%) [17]. The proportion
of lesions with absence of the classic CNVeither within or
beyond the area of the lesion identified at baseline was
stable from month 12 to month 24 in 37–39% of treated
patients in our study. In the VIP study the proportion of
lesions with absence of classic CNVeither within or beyond
the area of the lesion identified at baseline increased from
the month-12 (44%) to the month-24 examination (51%)
[17].
In summary, our study suggests that verteporfin therapy
can increase the chance of stabilizing or improving vision
compared with the placebo arm of the VIP trial [15–17] in
patients with subfoveal CNV caused by PM in a tertiary
ophthalmic center. Since most patients with CNV due to
PM are young and at employable age, stabilization of vi-
sual acuity and eventually restoring of reading ability is
extremely important.
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